Treatment of nonmuscle invading bladder cancer: Do physicians in the United States practice evidence based medicine?
Open Access
- 4 June 2009
- Vol. 115 (12), 2660-2670
- https://doi.org/10.1002/cncr.24311
Abstract
BACKGROUND: Phase 3 clinical trials performed primarily outside the US demonstrate that intravesical instillation of chemotherapy immediately after transurethral resection of the bladder (TURB) decreases cancer recurrence rates. The authors sought to determine whether US urologists have adopted this practice, and its potential effect on costs of bladder cancer (BC) care. METHODS: By using 1997‐2004 MEDSTAT claims data, the authors identified patients with newly diagnosed BC who underwent cystoscopic biopsy or TURB, and those who received intravesical chemotherapy within 1 day after TURB. Economic consequences of this treatment compared with TURB alone were modeled using published efficacy estimates and Medicare reimbursements. The authors used a time horizon of 3 years and assumed that this treatment was given for all newly diagnosed low‐risk BC patients. RESULTS: Between 1997 and 2004, the authors identified 16,748 patients with newly diagnosed BC, of whom 14,677 underwent cystoscopic biopsy or TURB. Of these, only 49 (0.33%) received same‐day intravesical instillation of chemotherapy. From 1997 through 2004, there has been little change in the use of this treatment. The authors estimated a 3‐year savings of $538 to $690 (10% to 12%) per patient treated with TURB and immediate intravesical chemotherapy compared with TURB alone, reflecting a yearly national savings of $19.8 to $24.8 million. CONCLUSIONS: Instillation of intravesical chemotherapy immediately after TURB has not been embraced in the US. Adopting this policy would significantly lower the cost of BC care. Cancer 2009. © 2009 American Cancer Society.Keywords
This publication has 44 references indexed in Scilit:
- Long‐term outcome of hematuria home screening for bladder cancer in menCancer, 2006
- Randomized Prospective Phase III Trial of Difluoromethylornithine vs Placebo in Preventing Recurrence of Completely Resected Low Risk Superficial Bladder CancerJournal of Urology, 2006
- Cancer Statistics, 2006CA: A Cancer Journal for Clinicians, 2006
- Identification of Individuals With CKD From Medicare Claims Data: A Validation StudyAmerican Journal of Kidney Diseases, 2005
- The Economic Burden of Anemia in Cancer Patients Receiving ChemotherapyValue in Health, 2005
- Intravesical Therapy for Superficial Bladder Cancer: Slow but Steady ProgressJournal of Clinical Oncology, 2003
- Guidelines on Bladder CancerEuropean Urology, 2002
- BLADDER CANCER CLINICAL GUIDELINES PANEL SUMMARY REPORT ON THE MANAGEMENT OF NONMUSCLE INVASIVE BLADDER CANCER (STAGES Ta, T1 AND TIS)Journal of Urology, 1999
- TRANSURETHRAL RESECTION WITH PERIOPERATIVE INSTILLATION OF INTERFERON-alpha OR EPIRUBICIN FOR THE PROPHYLAXIS OF RECURRENT PRIMARY SUPERFICIAL BLADDER CANCER: A PROSPECTIVE RANDOMIZED MULTICENTER STUDY-FINNBLADDER IIIJournal of Urology, 1999
- Single Dose Intravesical Thiotepa as an Adjuvant to Cystodiathermy in the Treatment of Transitional Cell Bladder CarcinomaBJU International, 1976